Botulinum Toxin in the Management of Children with Cerebral Palsy
Top Cited Papers
Open Access
- 1 July 2019
- journal article
- review article
- Published by Springer Nature in Pediatric Drugs
- Vol. 21 (4) , 261-281
Abstract
During the past 25 years, botulinum toxin type A (BoNT-A) has become the most widely used medical intervention in children with cerebral palsy. In this review we consider the gaps in our knowledge in the use of BoNT-A and reasons why muscle morphology and function in children with cerebral palsy are impaired. We review limitations in our knowledge regarding the mechanisms underlying the development of contractures and the difficulty in preventing them. It is clear from this review that injection of BoNT-A in the large muscles of both the upper and lower limbs of children with cerebral palsy will result in a predictable decrease in muscle activity, which is usually reported as a reduction in spasticity, for between 3 and 6 months. These changes are noted by the use of clinical tools such as the Modified Ashworth Scale and the Modified Tardieu Scale. Decreased muscle over-activity usually results in improved range of motion in distal joints. Injection of the gastrocnemius muscle for toe-walking in a child with hemiplegia or diplegia usually has the effect of increasing the passive range of dorsiflexion at the ankle. In our review, we found that this may result in a measurable improvement in gait by the use of observational gait scales or gait analysis, in some children. However, improvements in gait function are not always achieved and are small in magnitude and short lived. We found that some of the differences in outcomes in clinical trials may relate to the use of adjunctive interventions such as serial casting, orthoses, night splints and intensive therapy. We note that the majority of clinical trials of the use of BoNT-A in children with cerebral palsy have focussed on a single injection cycle and this is insufficient to understand the balance between benefit and harm. Most outcomes were reported in terms of changes in muscle tone and there were fewer studies with robust methodology that reported improvements in function. Changes in the domains of activities and participation have rarely been reported in studies to date. There were no clinical reviews to date that consider the findings of studies in human volunteers and in experimental animals and their relevance to clinical protocols. In this review we found that studies in human volunteers and in experimental animals show muscle atrophy after an injection of BoNT-A for at least 12 months. Muscle atrophy was accompanied by loss of contractile elements in muscle and replacement with fat and connective tissue. It is not currently known if these changes, mediated at a molecular level, are reversible. We conclude that there is a need to revise clinical protocols by using BoNT-A more thoughtfully, less frequently and with greatly enhanced monitoring of the effects on injected muscle for both short-term and long-term benefits and harms.Keywords
Funding Information
- National Health and Medical Research Council (CRE-CP)
This publication has 127 references indexed in Scilit:
- Do skeletal muscle properties recover following repeat onabotulinum toxin A injections?Journal of Biomechanics, 2013
- Assessment Tools and Classification Systems Used For the Upper Extremity in Children With Cerebral PalsyClinical Orthopaedics and Related Research, 2012
- Definition and classification of hyperkinetic movements in childhoodMovement Disorders, 2010
- Practice Parameter: Pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review)Neurology, 2010
- Repeat botulinum toxin‐A injections in the upper limb of children with hemiplegia: a randomized controlled trialDevelopmental Medicine & Child Neurology, 2009
- Bilateral pallidal deep brain stimulation for the treatment of patients with dystonia-choreoathetosis cerebral palsy: a prospective pilot studyThe Lancet Neurology, 2009
- Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): [RETIRED]Neurology, 2008
- Reliability of Ashworth and Modified Ashworth Scales in Children with Spastic Cerebral PalsyBMC Musculoskeletal Disorders, 2008
- Therapeutic choices in the locomotor management of the child with cerebral palsy---more luck than judgement?Archives of Disease in Childhood, 2001
- Objective measurement of clinical findings in the use of botulinum toxin type A for the management of children with cerebral palsyEuropean Journal of Neurology, 1999